Tanshinone IIA inhibits oral squamous cell carcinoma via reducing Akt-c-Myc signaling-mediated aerobic glycolysis

Li, Ming; Gao, Feng; Zhao, Qing; Zuo, Huilan; Liu, Wenbin; Li, Wei

doi:10.1038/s41419-020-2579-9

Cited by 52 publications

(52 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…c-MYC, an important downstream transcription factor of the MAPK signaling pathway, is a protooncogene with an abnormal expression related to many cancers [36][37][38][39][40][41][42]. It also has been reported that reducing c-MYC can inhibit OSCC [43,44]. Moreover, the ubiquitination of DUSP6 can activate c-MYC, promoting the invasion of endometrial stromal cells [45].…”

Section: Discussionmentioning

confidence: 99%

Angelicin Shows Antitumor Effects On The Oral Squamous Cell Carcinoma By Negatively Regulating DUSP6-Mediated cMYC-MAPK Signaling Pathway

Liu¹,

Shang²,

Qi³

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Angelicin has been reported to have antitumor effects on many cancers. However, few studies on angelicin in oral squamous cell carcinoma (OSCC) have been performed. Methods: In this study, we performed a cell cycle and apoptosis assay, wound healing assay, and transwell assay to assess the effects of angelicin on malignant phenotypes of OSCC in vitro. To determine the potential regulatory mechanism, we conducted differentially expressed genes analysis of OSCC cells. Subsequently, nude mouse xenograft models were used to evaluate the function of angelicin and validate the regulatory mechanism in vivo. Results: The results showed that angelicin inhibited the malignant phenotype of OSCC in vitro and reduced tumor formation in vivo. Mechanistically, angelicin induced the downregulation of the significantly different gene—dual-specificity phosphatase 6 (DUSP6) and the downstream transcription factor c-MYC in the mitogen-activated protein kinase (MAPK) signaling pathway. Conclusion: Our results indicate that angelicin has antitumor effects on OSCC by negatively regulating the DUSP6-mediated cMYC-MAPK signaling pathway and is a promising antitumor drug in OSCC therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Angelicin Shows Antitumor Effects On The Oral Squamous Cell Carcinoma By Negatively Regulating DUSP6-Mediated cMYC-MAPK Signaling Pathway

Liu¹,

Shang²,

Qi³

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…The combination of anti-ABCG2 monoclonal antibody EPI MBS+mAb and ultrasound treatment can reduce the clonal ability of MM CD138 − CD34 − CSC isolated from a human MM RPMI 8226 cell line and inhibit tumorigenesis in nude mice [ 32 ]. In addition, natural products are considered biocompatible and reliable treatments for human cancer [ 33 , 34 ]. Diallyl thiosulfinatecan enhances the inhibitory effect of dexamethasone on SP cells [ 35 ].…”

Section: Markers Of Mmscs and Drugs Targeting Themmentioning

confidence: 99%

Identification and Characterization of Multiple Myeloma Stem Cell-Like Cells

Guo

Wang

Chen

et al. 2021

Cancers

View full text Add to dashboard Cite

Multiple myeloma (MM) is a B-cell tumor of the blood system with high incidence and poor prognosis. With a further understanding of the pathogenesis of MM and the bone marrow microenvironment, a variety of adjuvant cell therapies and new drugs have been developed. However, the drug resistance and high relapse rate of MM have not been fundamentally resolved. Studies have shown that, in patients with MM, there is a type of poorly differentiated progenitor cell (MM stem cell-like cells, MMSCs). Although there is no recognized standard for identification and classification, it is confirmed that they are closely related to the drug resistance and relapse of MM. This article therefore systematically summarizes the latest developments in MMSCs with possible markers of MMSCs, introduces the mechanism of how MMSCs work in MM resistance and recurrence, and discusses the active pathways that related to stemness of MM.

show abstract

“… Kim et al (2020) have found that genipin can increase the expression of p53 and DRAM, induce apoptosis and autophagy, and enhance the sensitivity of AGS and MKN45 gastric cancer cell lines to OXA. Tanshinones are a group of abietane diterpenes from the TCM Danshen and have exhibited anticancer activities in vitro and in vivo ( Li M. et al, 2020 ). Xu Z. et al (2018) have reported that tanshinone IIA can reduce the expression of multidrug resistance protein 1 (MRP1) and inhibit the efflux of adriamycin (ADM).…”

Section: Modulatory Effects Of Autophagy Inhibitors and Activators Onmentioning

confidence: 99%

The Role of Autophagy in Gastric Cancer Chemoresistance: Friend or Foe?

Tang

et al. 2020

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Gastric cancer is the third most common cause of cancer-related death worldwide. Drug resistance is the main inevitable and vital factor leading to a low 5-year survival rate for patients with gastric cancer. Autophagy, as a highly conserved homeostatic pathway, is mainly regulated by different proteins and non-coding RNAs (ncRNAs) and plays dual roles in drug resistance of gastric cancer. Thus, targeting key regulatory nodes in the process of autophagy by small molecule inhibitors or activators has become one of the most promising strategies for the treatment of gastric cancer in recent years. In this review, we provide a systematic summary focusing on the relationship between autophagy and chemotherapy resistance in gastric cancer. We comprehensively discuss the roles and molecular mechanisms of multiple proteins and the emerging ncRNAs including miRNAs and lncRNAs in the regulation of autophagy pathways and gastric cancer chemoresistance. We also summarize the regulatory effects of autophagy inhibitor and activators on gastric cancer chemoresistance. Understanding the vital roles of autophagy in gastric cancer chemoresistance will provide novel opportunities to develop promising therapeutic strategies for gastric cancer.

show abstract

Tanshinone IIA inhibits oral squamous cell carcinoma via reducing Akt-c-Myc signaling-mediated aerobic glycolysis

Cited by 52 publications

References 54 publications

Angelicin Shows Antitumor Effects On The Oral Squamous Cell Carcinoma By Negatively Regulating DUSP6-Mediated cMYC-MAPK Signaling Pathway

Angelicin Shows Antitumor Effects On The Oral Squamous Cell Carcinoma By Negatively Regulating DUSP6-Mediated cMYC-MAPK Signaling Pathway

Identification and Characterization of Multiple Myeloma Stem Cell-Like Cells

The Role of Autophagy in Gastric Cancer Chemoresistance: Friend or Foe?

Contact Info

Product

Resources

About